Crossmark

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study

Crossref DOI link: https://doi.org/10.1007/s12149-026-02169-1

Published Online: 2026-02-12

Published Print: 2026-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kobayashi, Noritoshi https://orcid.org/0000-0002-9181-3722
Ono, Hiroaki

Okubo, Naoki

Akahoshi, Keiichi

Kudo, Atsushi

Ban, Daisuke

Ichikawa, Yasushi
Funding

Funding for this research was provided by:

Novartis Pharma K.K. (CABC123DJP01T)
License Information

Text and Data Mining valid from 2026-02-12

Version of Record valid from 2026-02-12
More Information

Article History

Received: 20 December 2025

Accepted: 6 February 2026

First Online: 12 February 2026

Declarations

:

: Noritoshi Kobayashi received an honorarium from Novartis. K.K., Teijin Pharma, Teijin Healthcare, EA Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, Yakult Honsha, Taiho Pharmaceutical, Yakult Honsha, MSD, and PD Radiopharma (successor to the radiopharmaceutical business of Fujifilm Toyama Chemical Co., Ltd.) and received support for research expenses from Novartis. K.K. The other authors declare no conflicts of interest. The funder had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or the decision to publish the results.

Document is current

Any future updates will be listed below